Prima Biomed - Interim CVac data

Wednesday, Oct 17 2012 by

Oct 17th 2012 - Edison Investment Research today published a report on Prima Biomed entitled "Interim CVac Data". In summary, the report says:

Interim data from the 63-patient CAN-003 Phase IIb trial of Prima’s CVac immunotherapeutic in ovarian cancer in first or second remission showed safety and some preliminary evidence of activity. However, the lack of a more definitive signal, even though this would be unlikely to be seen at this point, caused a 12% sell-off in Prima’s shares. Full data from this study, which may provide this proof of concept, are due in c 12 months’ time. However, Prima’s investment case hinges on the outcome of a larger 1,000 patient CANVAS Phase II/III study of CVac, given as first line maintenance in ovarian cancer, for which data are due in March 2015.

About Edison Investment Research

Edison Investment Research


Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority ( more »